Skip to content

Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00067405
Enrollment
40
Registered
2003-08-20
Start date
2004-06-30
Completion date
2007-07-31
Last updated
2008-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Fibromyalgia, Intravenous micronutrient therapy, IVMT, alternative medicine, complementary medicine, vitamins, vitamin supplements

Brief summary

The purpose of this study is to determine if intravenous micronutrient therapy (IVMT) is effective in the treatment of fibromyalgia, as assessed by validated functional and pain measures.

Detailed description

As per Brief Summary

Interventions

DRUGIntravenous micronutrient therapy

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Meet the American College of Rheumatology criteria for Fibromyalgia diagnosis; * On no medication for Fibromyalgia other than acetaminophen, or willing to stop all such medication for the duration of the study * Willing to stop all FMS medication for the duration of the study or be on a stable dose of such medication for at least 3 months

Exclusion criteria

* Other concurrent medical conditions such as rheumatologic disease, chronic infection, untreated endocrine disorders, unstable seizures, psychiatric disorders, acute peptic ulcer disease, congestive heart failure, chronic liver disorders and/or bleeding problems * Allergy to thiamin * Unwilling to stop vitamin supplementation for the duration of the study * PLEASE NOTE: Travel to and accomodations at the study site can NOT be compensated. Anyone wishing to travel from outside of the study site's geographic area must do so at their own risk and expense.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026